http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개선된 사람 혈장중 세파클러 농도 정량법을 이용한 세파클러 캡슐의 생체이용률 측정
김태완,송옥경,한선영,Cao, Qing-Ri,박미진,강성화,신관석,Cui, Jing-Hao,이범진 한국약제학회 2005 Journal of Pharmaceutical Investigation Vol.35 No.2
After establishing improved HPLC analytical method ofcefaclor in human plasma samples, a bioavailability study of cefaclor capsules was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). The standard calibration curve using an HPLC with UV detector was constructed in a range of 0.0324--16 μg/m1. The 6% perchloric acid instead of 6% trichloroacetic acid was used to precipitate plasma protein. The HPLC chromatograms were precisely and accurately resolved when spiked with human plasma spiked with cefaclor and cephalexin (internal standard). Twenty healthy male Korean volunteers received two commercial cefaclor capsules, Neocef ' capsule (Jinyang Pharm. Co., Ltd) or Ceclor" capsule {Lilly Korea. Co., Ltd.) at the 250 mg cefaclor in a 2 x 2 crossover study. There was a one-week washout period between the doses. Plasma concentrations of cefaclor were monitored for 8 hours after oral drug administration. AUC, the area under the plasma concentration-time curve from time zero to 8 hr (13 points), was calculated by the linear trapezoidal rule method. C,,,a" (maximum plasma drug concentration) and Tmax (time to reach Cma,) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed AUC, and Cmax. No significant sequence effect was found for all of the bioavailability parameters indicating that the cross-over design was properly performed. The 90% confidence intervals of the AUC, ratio and the Cmax ratio for Neocer/Ceclor" were 0.9049 S S < 1.0304 and 0.9776 5 S 1.226, respectively. These values were within the acceptable bioequivalence intervals of 0.80-1.25. Thus, our study demonstrated the bioequivalence of Neocef"/Ceclor" with respect to the extent of absorption.
우리나라 사람면역결핍바이러스(Human Immunodeficiency Virus) 감염환자에서 발병한 악성종양
최평균,송진수,조재현,김성한,박경화,방지환,박완범,김홍빈,김동완,김태유,허대석,오명돈,김남중,최강원 대한감염학회 2006 감염과 화학요법 Vol.38 No.6
Background : Since highly active antiretroviral therapy has lengthened the life span of individuals infected with human immunodeficiency virus (HIV), the importance of malignancy associated with HIV has been increased. The relative frequencies of malignancies in HIV infected patients may vary in different race and region. The aim of this study is to determine the prevalence and characteristics of malignancies in patients with HIV infection in South Korea. Materials and Methods : To identify HIV patients with malignancy, we reviewed the electronic database of pathological reports for all HIV-infected patients seen from January 1986 to December 2005 at the Seoul National University Hospital. We retrospectively reviewed the medical records of them. Results : Among 850 patients infected with HIV, 33 episodes of malignant diseases were diagnosed in 32 patients (3.76%). Thirty were males, and median age was 46 years (range 29-70). At the time of the diagnosis of malignancy, median CD4^(+) lymphocytes count was 100/uL (range 5-620) and in 27 (82%) patients, CD4^(+) lymphocytes count were less than 200/uL. For 13 patients (40%), malignancy was initial presentation of HIV infection. Excluding patients initially diagnosed as malignancy, median follow-up duration from the first visit to diagnosis of malignancy was 36 months (range 3-96). Non-Hodgkin's lymphoma was the most frequent malignancy (13 patients), followed by Kaposi's sarcoma (7), Hodgkin‘s disease (3), acute myeloid leukemia (1), and other solid cancer (9) including one case of anal cancer associated with human papillomavirus. Among 13 patients with non- Hodgkin's lymphoma, 4(31%) achieved the complete remission after chemotherapy and/or radiation therapy, and had been followed without evidence of recurrence. Conclusion : Malignancy was diagnosed in 3.76% of patients infected with HIV. Non-Hodgkin‘s lymphoma is the most prevalent malignancy in HIV patients in South Korea. 목적 : 효과적인 항레트로바이러스 다제요법이 도입됨에 따라, HIV 감염환자들의 수명이 증가되었고, 이에 따라 HIV 감염환자에서 악성종양의 중요성 또한 증가하고 있다. 본 연구의 목적은 우리나라 HIV 감염환자에서 악성종양의 유병률과 호발하는 악성종양의 특성을 밝히는 것이다. 재료 및 방법 : 1986년부터 2005년까지 서울대학교병원에서 치료를 받은 HIV 감염환자의 의무기록을 후향적으로 분석하였고, 병리학적 검사 결과를 검토하여 악성종양이 진단된 환자들을 대상으로 연구를 시행하였다. 결과 : 총 850명의 환자 중, 32명(3.76%)에서 33예의 악성종양이 진단되어, 악성종양의 발병률은 1,000인년 당13.0명(95% 신뢰구간: 8.6∼17.4명)이었다. 그 중 남자는 30명이었고, 악성종양 진단 당시 연령의 중간값은 46 (29-70)세이었다. 악성종양 진단받을 당시, CD4 림프구 수의 중간값은 lOO/uL (5-620 uL) 이었고, CD4 림프구수가 200/ uL 미만인 환자가 27명(82%)이었다. 악성종양에 대한 검사 도중에 HIV 감염사실이 밝혀진 환자가 13명(40%)이었다. HIV를 진단 받은 후 악성종양이 발병한 환자들에서, HIV 진단 후 악성종양의 발병까지는 평균 36개월(3-96개월)이 걸렸다. 13명의 HIV 감염 환자에서 진단된 비호지킨림프종이 가장 흔한 악성종양이었고, 이외에 카포시육종이 7명, 호지킨병이 3명, HPV와 연관된 항문암이 1명의 HIV 환자에서 진단되었다. 그 밖에 급성백혈병, 방광암, 췌장장, 폐암, 진행성위암, 갑상선암, 간세포암, 후두암이 각각 1예씩 진단되었다. 비호지킨림프종이 진단된13명 환자 중, 4명(31%)은 항암치료 및 방사선치료를 받아 완전관해가 되었고, 현재 재발의 증거 없이 외래에서 경과 관찰 중이다. 결론 : 우리나라 HIV 감염환자에서 악성종양의 유병률은 3.76%이었고, 비호지킨림프종이 가장 흔한 악성종양이었다.
Chaetoglobosin A, an Inhibitor of Bleb Formation on K562 Cells Induced by Phorbol 12,13-Dibutyrate
KO, HACK-RYONG,KIM, BO YEON,AHN, SOON-CHEOL,OH, WON KEUN,KIM, JIN-HEE,LEE, HYUN SUN,KIM, HWAN-MOOK,HAN, SANG-BAE,MHEEN, TAE0ICK,AHN, JONG-SEOG 한국미생물 · 생명공학회 1998 Journal of microbiology and biotechnology Vol.8 No.6
한석태(Seog-Tae Han),강지만(Jinman Kang),이정원(Jeong-Won Lee),제도흥(Do-Hyung Je),정문희(Moon-Hee Jung),김수연(Soo-Yeon Kim),위석오(Seog-Oh Wi) 한국전자파학회 2010 한국전자파학회논문지 Vol.21 No.11
본 논문에서는 밀리미터파 수신 시스템의 준광학계 회로에서 발생되는 3가지 빔 결합 손실에 대하여 가우시언 빔 전송 이론을 기반으로 심도 있게 검토하였다. 첫째, 준광학 시스템에 의하여 형성된 각각의 빔 허리와 그들의 위치가 서로 일치되지 않았을 때 발생되는 빔 결합 손실에 대하여 분석하였다. 빔 허리의 크기를 3 이상으로 설계하면 빔 광축 방향에 대한 빔 허리 크기와 그 위치의 불일치에 의한 빔 결합 손실을 최소화 시킬수 있다. 둘째, 준광학 회로에서 서로 다른 두 빔 축의 기울어짐과 각도상의 비정렬에 의한 빔 결합 손실을 해석하였다. 기울기 각도와 정렬에 의한 빔 결합 손실을 고려할 때 빔 허리의 크기가 작을수록 유리함을 알 수 있다. 마지막으로 광축 방향에 대하여 측면 방향으로 하나의 광축이 치우쳐 있는 경우의 결합 손실을 검토하였다. 치우침을 감안한 설계 빔의 반경은 최소한 3 이상이 되도록 설계되어야 한다. In this paper, three kinds of beam coupling losses which occur in a quasi-optics circuit for millimeter wave receiver system have been intensively investigated. First, the beam coupling losses which are caused by mismatch of beam waists radii and their positions between those of one and the other have been evaluated. It shows that beam coupling losses due to mismatch of beam waists radii and their positions between two quasi-optics circuits can be minimized if beam waist radius is chosen as larger than 3 times the operation wavelength. Second, the beam coupling losses have been studied when the axis of propagation of one beam is tilted with respect to that of the other beam. It is noted that smaller beam waist radius results in greater tolerance to tilts and angular misalignments. Third, the beam coupling cases in which two beams are offset if their axes of propagation are parallel but one is displaced relative to the other have been investigated. It is confirmed that beam waists radii with larger than 3 times operation wavelength are less sensitive to lateral offsets.